Taraporevala Cyrus 4

What Happened Cyrus Taraporevala, a member of Pfizer's Board of Directors, was granted 1,386.834 phantom shares (derivative units) on 2026-03-27 at a reported per-unit value of $27.04, for a total value of $37,500. This was recorded on Form 4 as an award/grant (transaction code A) for deferred director compensation rather than an open-market purchase.

Key Details

• Transaction date: 2026-03-27; Form 4 filed 2026-03-30 (timely filing).
• Units granted: 1,386.834 phantom shares at $27.04 per unit; total reported value $37,500.
• Type: Derivative award (phantom units) representing deferred director compensation, not an immediate issuance of common stock.
• Shares owned after transaction: Not disclosed in this filing.
• Footnotes:
  • F1: Each unit equals one phantom share of common stock.
  • F2: These units are deferred director compensation (including dividend equivalents) and will be settled in cash or common stock at the director’s election following his retirement from the Board.
• Accession: 0001225208-26-004089.

Context Phantom share awards are a form of deferred pay tied to company stock value; they do not represent immediate common stock ownership and are settled later in cash or stock per the director’s election. Such awards are routine for board members and do not necessarily indicate a buy or sell signal about the director’s view on the company.